Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 24, 1996
Grant Date -
N/A
app pub date -
Nov 6, 1992
filing date -
Mar 6, 1991
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Humanized and chimeric anti-epidermal growth factor receptor (anti-EGF-R) monoclonal antibodies are disclosed, comprising an artificial modified consensus sequence for the heavy chain of the framework region of the variable region of a human immunoglobulin. Corresponding humanized and chimeric monoclonal antibodies which bind to epitopes of the epidermal growth factor receptor (EGF-R) having specific amino acid sequences in the hypervariable regions responsible for EGF-R binding are also disclosed. These antibodies are therapeutically and diagnostically useful.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully